NCT01954992 2024-12-31
Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer
Eleison Pharmaceuticals LLC.
Phase 3 Recruiting
Clinical Trials
9 trialsNCT00441467 2015-03-25
Safety and Efficacy Study of Glufosfamide in Previously Treated Advanced Soft Tissue Sarcoma
Eleison Pharmaceuticals LLC.
Phase 2 Completed
NCT00442598 2015-03-10
Safety and Efficacy Study of Glufosfamide in Ovarian Cancer
Eleison Pharmaceuticals LLC.
Phase 2 Terminated
NCT00005053 2012-09-24
Glufosfamide With or Without Hydration in Treating Patients With Advanced Pancreatic Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT00005055 2012-09-24
Glufosfamide With of Without Hydration in Treating Patients With Advanced Non-small Cell Lung Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT00014300 2012-09-24
Glufosfamide in Treating Patients With Recurrent Glioblastoma Multiforme
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT00099294 2009-04-30
Study of the Efficacy and Safety of Glufosfamide Compared With Best Supportive Care in Metastatic Pancreatic Cancer
Threshold Pharmaceuticals
Phase 3 Completed
NCT00102752 2009-04-30
Study of Safety and Efficacy of Glufosfamide in Combination With Gemcitabine in Cancer
Threshold Pharmaceuticals
Phase 1/2 Completed
NCT00435578 2009-04-30
Safety and Efficacy Study of Glufosfamide in Patients With Recurrent Sensitive Small Cell Lung Carcinoma
Threshold Pharmaceuticals
Phase 2 Terminated